Wong HL - Search Results

1

Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization.

Xue HY, Wong HL. Xue HY, et al. Among authors: wong hl. Biomaterials. 2011 Apr;32(10):2662-72. doi: 10.1016/j.biomaterials.2010.12.029. Epub 2011 Jan 14. Biomaterials. 2011. PMID: 21236485

2

A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.

Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. Wong HL, et al. J Pharmacol Exp Ther. 2006 Jun;317(3):1372-81. doi: 10.1124/jpet.106.101154. Epub 2006 Mar 17. J Pharmacol Exp Ther. 2006. PMID: 16547167

3

Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner.

Xue HY, Wong HL. Xue HY, et al. Among authors: wong hl. ACS Nano. 2011 Sep 27;5(9):7034-47. doi: 10.1021/nn201659z. Epub 2011 Aug 18. ACS Nano. 2011. PMID: 21838301

4

Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.

Xue HY, Wong HL. Xue HY, et al. Among authors: wong hl. Eur J Pharm Biopharm. 2012 May;81(1):24-32. doi: 10.1016/j.ejpb.2012.02.005. Epub 2012 Feb 18. Eur J Pharm Biopharm. 2012. PMID: 22369881

5

A novel hybrid delivery system: polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA).

Narvekar M, Xue HY, Wong HL. Narvekar M, et al. Among authors: wong hl. Int J Pharm. 2012 Oct 15;436(1-2):721-31. doi: 10.1016/j.ijpharm.2012.07.042. Epub 2012 Jul 28. Int J Pharm. 2012. PMID: 22850294

6

Lipid encapsulation of cationic polymers in hybrid nanocarriers reduces their non-specific toxicity to breast epithelial cells.

Xue HY, Narvikar M, Zhao JB, Wong HL. Xue HY, et al. Among authors: wong hl. Pharm Res. 2013 Feb;30(2):572-83. doi: 10.1007/s11095-012-0902-6. Epub 2012 Nov 8. Pharm Res. 2013. PMID: 23135818

7

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.

Xue HY, Liu S, Wong HL. Xue HY, et al. Among authors: wong hl. Nanomedicine (Lond). 2014 Feb;9(2):295-312. doi: 10.2217/nnm.13.204. Nanomedicine (Lond). 2014. PMID: 24552562 Free PMC article. Review.

8

Nanocarrier for poorly water-soluble anticancer drugs--barriers of translation and solutions.

Narvekar M, Xue HY, Eoh JY, Wong HL. Narvekar M, et al. Among authors: wong hl. AAPS PharmSciTech. 2014 Aug;15(4):822-33. doi: 10.1208/s12249-014-0107-x. Epub 2014 Apr 2. AAPS PharmSciTech. 2014. PMID: 24687241 Free PMC article. Review.

9

A new nanostructured carrier design including oil to enhance the pharmaceutical properties of retinoid therapy and its therapeutic effects on chemo-resistant ovarian cancer.

Narvekar M, Xue HY, Tran NT, Mikhael M, Wong HL. Narvekar M, et al. Among authors: wong hl. Eur J Pharm Biopharm. 2014 Sep;88(1):226-37. doi: 10.1016/j.ejpb.2014.04.014. Epub 2014 May 9. Eur J Pharm Biopharm. 2014. PMID: 24816129

10

Lipid-Based Nanocarriers for RNA Delivery.

Xue HY, Guo P, Wen WC, Wong HL. Xue HY, et al. Among authors: wong hl. Curr Pharm Des. 2015;21(22):3140-7. doi: 10.2174/1381612821666150531164540. Curr Pharm Des. 2015. PMID: 26027572 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

454 results

Search Page

Filters